Skip to main content
. 2025 Jul 8;16:1585556. doi: 10.3389/fimmu.2025.1585556

Figure 1.

Diagram comparing three CAR-engineered cellular therapeutics for relapsed/refractory large B-cell lymphoma. Panel 1 describes autologous CAR-T cells with advantages like FDA approval and a manageable safety profile, and disadvantages like complex manufacturing. Panel 2 features allogeneic CAR-T cells with benefits including off-the-shelf potential but requiring genetic edits. Panel 3 outlines allogeneic CAR-NK cells with an exceptional safety profile and innate killing capabilities, requiring IL-15 armoring for persistence. Each panel highlights mechanisms and cell sources.

Conceptual depicting characteristics of autologous and allogeneic CAR-engineered cellular therapeutics.